Cantor Fitzgerald initiated coverage on Novan with a new price target
$NOVN
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Novan with a rating of Overweight and set a new price target of $30.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2021 | $28.00 → $24.00 | Buy | HC Wainwright & Co. |
| 7/9/2021 | $30.00 | Overweight | Cantor Fitzgerald |
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $24.00 from $28.00 previously
Cantor Fitzgerald initiated coverage of Novan with a rating of Overweight and set a new price target of $30.00
HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $28.00 from $20.00 previously
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w
Ligand provides bridge and debtor-in-possession ("DIP") financing to Novan Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (NASDAQ:NOVN) ("Novan") for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand. The transaction is designed to preserve and maximize the value of Novan's commercial business and berdazimer gel development assets. Berdazimer gel is in development for molluscum contagiosum infe
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – Agreement provides a path forward for a product, if approved, to treat molluscum contagiosum, an unmet medical need – DURHAM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) and its wholly owned subsidiary, EPI Health, LLC (co
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference
2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received conditional acceptance from U.S. FDA for use of KINSOLUS™ as brand name for SB206, if approved – – First New Drug Application (NDA) remains on target with submission expected in Q3 2022 – DURHAM, N.C., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the appointment of Brian M. Johnson as its Chief Commercial Officer. Additionally, the Company received notice that the U.S. Food and Drug Administration (FDA) has conditionally accepted KI
– Dr. Maeda-Chubachi, who served as Novan's Senior Vice President, Medical has played a key role in the design and execution of the Company's development programs – – Dr. Maeda-Chubachi was instrumental in the execution of B-SIMPLE4, the Company's pivotal Phase 3 trial of SB206 in molluscum contagiosum, which recently reported positive topline efficacy and safety results – – Additionally, the Company announces Dr. Maeda-Chubachi's publication in JID Innovations based on previously completed Phase 3 studies (B-SIMPLE1 and B-SIMPLE2) suggesting SB206 may trigger the beginning-of-the-end ("BOTE") inflammation and shorten the duration of molluscum infection – DURHAM, N.C., Aug. 24, 2021 (GL
Pharmaceutical Services Leader Strengthens PPC's Capabilities and Enhances Strategic Initiative to Invest in Market-Leading Healthcare Companies Pritzker Private Capital ("PPC"), a leader in family direct investing, today announced the appointment of Paula Brown Stafford to the Pritzker Advisory Board. Ms. Stafford, currently Chairman and CEO of biotechnology company Novan, brings more than 30 years of healthcare industry experience to the Pritzker Advisory Board and PPC's family of companies. Her appointment will enhance PPC's initiatives to invest in and partner with market-leading healthcare companies, specifically in healthcare services, medical products, pharmaceutical services and th
SC 13D/A - Novan, Inc. (0001467154) (Subject)
SC 13G - Novan, Inc. (0001467154) (Subject)